Tom Trotter, AngioScore’s President &
CEO, discusses how the AngioSculpt significantly alters the landscape for treating both peripheral arterial disease (PAD) and coronary artery disease (CAD).

AngioScore develops, manufactures and markets the AngioSculpt Scoring Balloon Catheter for both the coronary and peripheral interventional markets. These markets represent a worldwide opportunity of over $2 billion. AngioSculpt combines a semi-compliant balloon with an innovative nitinol scoring element that uniquely cuts through plaque to open the target artery. The catheter is designed to address the limitations of conventional angioplasty balloon catheters, improve the deployment of drug-eluting stents through enhanced vessel preparation, and to provide safe and effective treatment options for complex and difficult-to-open vessels in the more than 4 million angioplasty procedures that are performed annually.